Placing an intraosseous (“I.O.”) device requires driving a needle and an obturator of an access assembly through the patient's skin and tissue until the needle tip is pressed against a surface of the bone cortex. Exemplary bones which can be accessed include the proximal tibia or humerus. The needle is then drilled, using a power driver (e.g. electrical or spring), manual awl, or the like, through the outer cortex of the bone until the tip enters the medullary cavity. The user then ceases drilling, and the obturator is removed leaving the hollow needle in place. The proximal needle hub is accessed and fluids can be introduced.
Currently, the user must make a subjective assessment of when the needle is correctly placed. The user “feels” the needle advance past the relatively hard and compact, cortex layer of the bone and penetrates into the relatively soft, medullary cavity of the bone. However, the relative density of the bone cortex compared with the medullary cavity can vary depending on the bone, size of medullary space, and the patient. Accordingly, the clinician relies on a subjective assessment of a “lack of resistance” in order to determine if the medullary cavity has been successfully accessed. Further, the user relies on a subjective assessment to ensure that the needle does not advance through the medullary space and penetrate a far wall of the medullary cavity. Some devices include a stopping feature that contacts a skin surface. However, skin and subcutaneous tissue thickness can vary greatly between patients, leading to missed placements.
Briefly summarized, embodiments disclosed herein are directed to apparatus and methods for a stepped needle for an intraosseous device that uses the outer surface of the bone cortex as a reference point. Since the thickness of the bone cortex does not vary significantly between patients, the accuracy of needle placement can be improved. The device includes a needle with a stepped increase in outer diameter disposed along the needle shaft. The abrupt change in outer diameter is sufficient to provide a substantial increase in insertion force. In an embodiment, the stepped increase in outer diameter prevents the needle from being inserted any further into the bone cortex. The distance from the needle tip to the stepped increase in outer diameter is sufficient to ensure the needle tip enters the medullary cavity while preventing impingement on a far wall of the medullary cavity.
Disclosed herein is a needle assembly for an intraosseous access system including, a needle supported by a needle hub and extending to a distal tip, and a stepped increase in diameter disposed on an outer surface of the needle at a predetermined distance from the distal tip, the stepped increase in diameter configured to penetrate a skin surface and abut against a bone cortex.
In some embodiments, the predetermined distance is configured to allow the distal tip to extend through the bone cortex and into a medullary cavity of a bone. The stepped increase in diameter is formed integrally with the needle. A distal surface of the stepped increase in diameter extends perpendicular to a longitudinal axis of the needle. A distal surface of the stepped increase in diameter extends at an angle to a longitudinal axis of the needle to define a tapered shape. The needle defines a lumen having a first needle lumen diameter disposed distally of the stepped increase in diameter, and a second needle lumen diameter disposed proximally of the stepped increase in diameter, the second needle lumen diameter being larger than the first needle lumen diameter. In some embodiments, the needle assembly for an intraosseous access system further includes a third needle lumen diameter disposed proximally of the second needle lumen diameter, the third needle lumen diameter being less than the second needle lumen diameter to define a bulged portion in the needle.
In some embodiments, the needle assembly further includes an obturator disposed within the needle lumen, an outer diameter of the obturator being equal to, or less than, the first needle lumen diameter. In some embodiments, the needle assembly further includes an overtube engaged with an outer surface of the needle, a distal tip of the overtube defining a portion of the stepped increase in diameter. A longitudinal length of the overtube is less than a longitudinal length of a shaft of the needle, the overtube being adhered to the outer surface of the needle to form a collar. The overtube is slidably or rotatably engaged with the needle.
In an embodiment, the overtube includes a metal, alloy, plastic, polymer, composite, or carbon-based composite material. The overtube includes a first material, and a second material different from the first material. The first material is a relatively softer material and can elastically or plastically deform, the second material is a harder material and can be resistant to any elastic or plastic deformation. The overtube is formed of concentric tubes including a first tube formed of one of the first material or the second material and disposed adjacent the needle, and a second tube disposed on an outer surface of the first tube and formed of one of the first material or the second material. The overtube is formed of adjacent tubes including a first tube formed of the first material and disposed distally of a second tube formed of the second material. A first portion of the overtube is formed the first material and extends annularly about the needle between 1° and 359°, and a second portion of the overtube is formed of the second material and extends annularly about the needle between 1° and 359°. The distal tip of the overtube is configured to blunt and increase in diameter on contact with a surface of the bone cortex.
In some embodiments, a proximal end of the overtube abuts against the needle hub to prevent further longitudinal movement of the distal tip of the needle. A first diameter of the needle hub is between 1 cm and 3 cm. The needle hub includes a flared portion extending to a second diameter, the second diameter being greater than the first diameter. The needle hub includes a proximal housing slidably or rotatably engaged with a distal housing. In some embodiments, the needle hub includes a biasing member configured to bias the distal housing towards a proximal position relative to the proximal housing. The distal housing includes a distal face configured to engage a skin surface. The overtube is slidably engaged with the needle between a retracted position and an extended position. The distal tip of the overtube extends distally of the distal tip of the needle in the extended position. In some embodiments, the needle assembly further includes an overtube biasing member configured to bias the overtube towards the extended position. In some embodiments, the needle assembly further includes a locking mechanism configured to retain the overtube in the retracted position when in a locked configuration.
In some embodiments, the needle assembly further includes an actuator configured to transition the locking mechanism between the locked configuration and an unlocked configuration. The actuator includes rotating or sliding the proximal housing relative to the distal housing. The overtube biasing member is configured to prevent the overtube from transitioning from the extended position to the retracted position. In some embodiments, the needle assembly further includes an abutment configured to engage the overtube in the extended position and prevent the overtube transitioning from the extended position to the retracted position. In some embodiments, one of the needle or the overtube includes graduated markings.
Also disclosed is a method of accessing a medullary cavity including, penetrating a bone cortex with a distal tip of a needle, the needle including a stepped increase in outer diameter disposed at a predetermined distance from the distal tip, the predetermined distance being greater than a thickness of the bone cortex, abutting the stepped increase in outer diameter against a surface of the bone cortex to prevent further distal advancement of the distal tip, and accessing the medullary cavity.
In some embodiments, the method further includes withdrawing an obturator from a lumen of the needle until a distal tip of the obturator is proximal of a stepped increase in diameter of the lumen to allow a proximal blood flow to be observed and confirm medullary access. An overtube is slidably or rotatably engaged with the needle, a distal surface of the overtube defining a portion of the stepped increase in outer diameter. In some embodiments, the method further includes abutting a proximal end of the overtube against a needle hub to prevent further distal advancement of the distal tip of the needle. In some embodiments, the method further includes abutting a distal surface of a distal housing of a needle hub against a skin surface, the distal housing slidably or rotatably engaged with a proximal housing to allow the distal tip to continue to advance distally to access the medullary cavity. In some embodiments, the method further includes biasing the distal housing towards a distal position relative to the proximal housing.
In some embodiments, the method further includes transitioning the overtube between a retracted position, where a distal surface of the overtube is disposed at a predetermined distance from the distal tip of the needle, and an extended position where a distal surface of the overtube is disposed distally of the distal tip of the needle. In some embodiments, the method further includes biasing the overtube to the extended position. In some embodiments, the method further includes locking the overtube in the retracted position. In some embodiments, the method further includes sliding or rotating the proximal housing relative to the distal housing to unlock the overtube and transition the overtube from the retracted position to the extended position. In some embodiments, the method further includes engaging an abutment with a portion of the overtube to prevent the overtube transitioning from the extended position to the retracted position.
A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
Before some particular embodiments are disclosed in greater detail, it should be understood that the particular embodiments disclosed herein do not limit the scope of the concepts provided herein. It should also be understood that a particular embodiment disclosed herein can have features that can be readily separated from the particular embodiment and optionally combined with or substituted for features of any of a number of other embodiments disclosed herein.
Regarding terms used herein, it should also be understood the terms are for the purpose of describing some particular embodiments, and the terms do not limit the scope of the concepts provided herein. Ordinal numbers (e.g., first, second, third, etc.) are generally used to distinguish or identify different features or steps in a group of features or steps, and do not supply a serial or numerical limitation. For example, “first,” “second,” and “third” features or steps need not necessarily appear in that order, and the particular embodiments including such features or steps need not necessarily be limited to the three features or steps. Labels such as “left,” “right,” “top,” “bottom,” “front,” “back,” and the like are used for convenience and are not intended to imply, for example, any particular fixed location, orientation, or direction. Instead, such labels are used to reflect, for example, relative location, orientation, or directions. Singular forms of “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
With respect to “proximal,” a “proximal portion” or a “proximal end portion” of, for example, a needle disclosed herein includes a portion of the needle intended to be near a clinician when the needle is used on a patient. Likewise, a “proximal length” of, for example, the needle includes a length of the needle intended to be near the clinician when the needle is used on the patient. A “proximal end” of, for example, the needle includes an end of the needle intended to be near the clinician when the needle is used on the patient. The proximal portion, the proximal end portion, or the proximal length of the needle can include the proximal end of the needle; however, the proximal portion, the proximal end portion, or the proximal length of the needle need not include the proximal end of the needle. That is, unless context suggests otherwise, the proximal portion, the proximal end portion, or the proximal length of the needle is not a terminal portion or terminal length of the needle.
With respect to “distal,” a “distal portion” or a “distal end portion” of, for example, a needle disclosed herein includes a portion of the needle intended to be near or in a patient when the needle is used on the patient. Likewise, a “distal length” of, for example, the needle includes a length of the needle intended to be near or in the patient when the needle is used on the patient. A “distal end” of, for example, the needle includes an end of the needle intended to be near or in the patient when the needle is used on the patient. The distal portion, the distal end portion, or the distal length of the needle can include the distal end of the needle; however, the distal portion, the distal end portion, or the distal length of the needle need not include the distal end of the needle. That is, unless context suggests otherwise, the distal portion, the distal end portion, or the distal length of the needle is not a terminal portion or terminal length of the needle.
As shown in
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
The present disclosure relates generally to intraosseous (“I.O.”) access devices, systems, and methods thereof.
In an embodiment, the system includes a driver 101 and an access assembly 109. The driver 101 can be used to rotate the access assembly 109 into a bone of a patient. In embodiments, the driver 101 can be automated or manual. In an embodiment, the driver 101 is an automated driver 108. For example, the automated driver 108 can be a drill that achieves high rotational speeds.
The intraosseous access system 100 can further include an obturator assembly 102, a shield 105, and a needle assembly 202, which may be referred to, collectively, as the access assembly 109. The access assembly 109 may also be referred to as an access system. The obturator assembly 102 is referred to as such herein for convenience. In an embodiment, the obturator assembly 102 includes an obturator 104. However, in some embodiments, the obturator 104 may be replaced with a different elongated medical instrument. As used herein, the term “elongated medical instrument” is a broad term used in its ordinary sense that includes, for example, such devices as needles, cannulas, trocars, obturators, stylets, and the like. Accordingly, the obturator assembly 102 may be referred to more generally as an elongated medical instrument assembly. In like manner, the obturator 104 may be referred to more generally as an elongated medical instrument.
In an embodiment, the obturator assembly 102 includes a coupling hub 103 that is attached to the obturator 104 in any suitable manner (e.g., one or more adhesives or overmolding). The coupling hub 103 can be configured to interface with the driver 101. The coupling hub 103 may alternatively be referred to as an obturator hub 103 or, more generally, as an elongated instrument hub 103.
In an embodiment, the shield 105 is configured to couple with the obturator 104. The coupling can permit relative longitudinal movement between the obturator 104 and the shield 105, such as sliding, translating, or other movement along an axis of elongation (i.e., axial movement), when the shield 105 is in a first operational mode, and can prevent the same variety of movement when the shield 105 is transitioned to a second operational mode. For example, as further discussed below, the shield 105 may couple with the obturator 104 in a manner that permits longitudinal translation when the obturator 104 maintains the shield 105 in an unlocked state, and when the obturator 104 is moved to a position where it no longer maintains the shield in the unlocked state, the shield 105 may automatically transition to a locked state in which little or no translational movement is permitted between the shield 105 and the obturator 104. Stated otherwise, the shield 105 may be longitudinally locked to a fixed or substantially fixed longitudinal orientation relative to the obturator 104 at which the shield 105 inhibits or prevents inadvertent contact with a distal tip of the obturator. In various embodiments, the shield 105 may be configured to rotate relative to the obturator 104 about a longitudinal axis of the obturator 104 in one or more of the unlocked or locked states.
With continued reference to
In an embodiment, the needle assembly 202 includes a needle hub 203 that is attached to the needle 204 in any suitable manner. The needle hub 203 can be configured to couple with the obturator hub 103 and may thereby be coupled with the driver 101, as further discussed below. The needle hub 203 may alternatively be referred to as a cannula hub 203.
In an embodiment, the shield 105 is configured to couple with the needle hub 203. The coupling can prevent relative axial or longitudinal movement between the needle hub 203 and the shield 105, such as sliding, translating, or the like, when the shield 105 is in the first operational mode, and can permit the shield 105 to decouple from the needle hub 203 when the shield 105 is transitioned to the second operational mode. For example, as further discussed below, the shield 105 may couple with the needle hub 203 so as to be maintained at a substantially fixed longitudinal position relative thereto when the obturator 104 maintains the shield 105 in the unlocked state, and when the obturator 104 is moved to a position where it no longer maintains the shield in the unlocked state, the shield 105 may automatically transition to a locked state relative to the obturator 104, in which state the shield 105 also decouples from the needle hub 203.
In an embodiment, the shield 105 can be coupled with the obturator 104, the obturator 104 can be inserted into the needle 204, and the obturator hub 103 can be coupled to the needle hub 203 to assemble the access assembly 109. In an embodiment, a cap 107 may be provided to cover at least a distal portion of the needle 204 and the obturator 104 prior to use of the access assembly 109. For example, in an embodiment, a proximal end of the cap 107 can be coupled to the obturator hub 103.
With continued reference to
The automated driver 108 can include an energy source 115 of any suitable variety that is configured to energize the rotational movement of the coupling interface 112. For example, in some embodiments, the energy source 115 may comprise one or more batteries that provide electrical power for the automated driver 108. In other embodiments, the energy source 115 can comprise one or more springs (e.g., a coiled spring) or other biasing member that may store potential mechanical energy that may be released upon actuation of the actuator 111.
The energy source 115 may be coupled with the coupling interface 112 in any suitable manner. For example, in an embodiment, the automated driver 108 includes an electrical, mechanical, or electromechanical coupling 116 to a gear assembly 117. In some embodiments, the coupling 116 may include an electrical motor that generates mechanical movement from electrical energy provided by an electrical energy source 115. In other embodiments, the coupling 116 may include a mechanical linkage that mechanically transfers rotational energy from a mechanical (e.g., spring-based) energy source 115 to the gear assembly 117. The automated driver 108 can include a mechanical coupling 118 of any suitable variety to couple the gear assembly 117 with the coupling interface 112. In other embodiments, the gear assembly 117 may be omitted.
In embodiments, the automated driver 108 can rotate the coupling interface 112, and thereby, can rotate the access assembly 109 at rotational speeds significantly greater than can be achieved by manual rotation of the access assembly 109. For example, in various embodiments, the automated driver 108 can rotate the access assembly 109 at speeds of between 200 and 3,000 rotations per minute. However, greater or lesser rotations per minute are also contemplated.
Further details and embodiments of the intraosseous access system 100 can be found in patent application publications: WO 2018/075694, WO 2018/165334, WO 2018/165339, and US 2018/0116693, each of which is incorporated by reference in its entirety into this application.
As shown in
In an embodiment, the needle 204, overtube 264, or combinations thereof, include graduated markings 266 to indicate a depth of the needle tip 205 and guide the user as to when the needle tip 205 is correctly placed. In an embodiment, the overtube 264 can be formed of a metal, alloy, plastic, polymer, composite, carbon-based composite, combinations thereof, or the like. In an embodiment, a first portion of the overtube 264 can be formed of a first material, and a second portion of the overtube 264 can be formed of a second material different from the first material. In an embodiment the first material and the second material can display different mechanical properties. In an embodiment, the first material can be formed of a metal, alloy, or the like, and the second material can be formed of a plastic, polymer, or the like.
As shown in
As shown in
In an embodiment, the needle 204 can include a third portion (not shown) disposed proximally of the proximal portion 276 that defines a needle lumen having a first diameter 268, i.e. a needle lumen that is less that the second lumen diameter 278. As such the proximal portion 276 defines a “bulged” portion disposed at a predetermined distance (x) from the needle tip, as described herein. In an embodiment, the predetermined distance (x) can be between 1 cm and 3 cm, however other predetermined distances are also possible and within the scope of the invention. In an embodiment, the bulged proximal portion 276 can include a stepped, tapered, or rounded increase in diameter and decrease in diameter, back to the diameter of the distal portion 274.
In the embodiments shown in
As shown in
In an embodiment, the overtube 264 is attached to the needle shaft by adhesive, welding, bonding, crimping or the like. Accordingly, the overtube 264 is fixed and unable to move relative to the needle 204. In an embodiment, the overtube 264 can extend over a portion of the needle 204. In an embodiment, a proximal end of the overtube 264 can extend to a point that is distal of the needle hub 203. In an embodiment, the overtube 264 can define a collar that is attached to the needle shaft as described herein.
In an embodiment, the overtube 264 is slidably engaged with the needle 204 and can be selectively secured in place. The position of a distal end of the overtube 264 can be adjusted relative to the needle tip 205 to a preferred distance along the longitudinal axis. The user can select a predetermined distance (x) depending on the type of target bone, the procedure, or age or health of the patient, or the like. For example, a predetermined distance (x) of 10 mm-15 mm would be preferable for smaller, pediatric patients, where a distance of 15 mm-30 mm would be preferable for larger, adult patients.
In an embodiment, the overtube 264 is rotatably engaged with the needle 204 about the longitudinal axis. This allows the needle 204 to spin freely while the overtube 264 remains substantially stationary. In an embodiment, the needle 204 can be drilled through the bone cortex 80 and the overtube 264 protects the surrounding tissues 70, 75 from twisting about the needle 204 as the needle spins. The overtube 264 therefore protects the tissues 70, 75 from damage and irritation. In an embodiment, the overtube 264 can be both slidably and rotatably engaged with the needle 204. Accordingly, the user can select a predetermined distance (x) between the distal end of the overtube 264 and the needle tip 205. Further the overtube can protect any surrounding tissue 70, 75 as the needle is drilled into the bone cortex 80.
In an embodiment, as shown in
As shown in
As shown in
In an embodiment, the second material 284 can provide structural support to overtube while the first material 282 can deform to increase the outer diameter of the overtube as it is urged against the bone cortex 80. To note the first material 282 can be sufficiently resilient to penetrate the skin surface tissues 70, 75 without deforming but can deform slightly, when urged against the bone cortex 80. Further, the relatively softer first material 282 can be configured to mitigate trauma to the bone cortex 80 as the needle 204 is rotated.
In an embodiment, a distal tip of the overtube 264, forming the stepped increase in diameter 254 can be formed of the first, relatively softer material 282. The tapered shape can facilitate penetrating the skin surface tissues 70, 75. Then, when the tapered stepped increase in diameter 254 contacts the relatively hard bone cortex 80, the tapered shape can deform and “mushroom” out, to abut against the bone cortex and provide an increase in resistance to distal advancement, as described herein. In an embodiment, the distal tip can mushroom out to a diameter that is greater than the outer diameter of the overtube 264 to provide a greater resistance to further distal advancement.
In an embodiment, as shown in
In an embodiment, as shown in
In an embodiment, the overtube 264 can be formed of a first quarter extending about the longitudinal axis of the needle 204 by 90° and formed of a first material 282, a second quarter disposed adjacent the first quarter, extending about the longitudinal axis of the needle 204 by 90° and formed of a second material 284, a third quarter disposed adjacent the second quarter, and extending about the longitudinal axis of the needle 204 by 90° and formed of a first material 282, and a fourth quarter disposed adjacent the third quarter, and extending about the longitudinal axis of the needle 204 by 90° and formed of a first material 282. It will be appreciated however, that other combinations of materials, and annular extensions, i.e. between 1° and 360°, of the different portions of the overtube 264 are also contemplated. In an embodiment, the overtube 264 can include a distal tip portion extending annularly about the needle 204 and formed of the first material 282. The distal tip portion can be configured to deform when contacting the bone cortex, as described herein.
In an embodiment, as shown in
With continuing reference to
As shown in
In an embodiment, the needle hub 203 can include one or more flared portions 303, for example a distal flared portion 303A and a proximal flared portion 303B. The flared portion 303 can extend annularly about the hub and provide an increased diameter (d2) relative to the diameter (d1) of the needle hub 203. Advantageously, the flared portion 303 can provide support for a user when urging the needle hub 203 along the longitudinal axis in either of the proximal or distal directions. Further the flared portion 303 can guide a user's fingers towards a longitudinal midpoint of the needle hub 203 and provide a secure grasp of the needle hub 203. This can be important in an emergency situations, where a user, who is often wearing gloves, would need to grasp the hub 203 rapidly and apply significant force to the needle hub 203, while avoiding slipping.
In an embodiment, the needle hub 203 can include a distal housing 304A and a proximal housing 304B that are slidable engaged with each other, for example, in a telescoping manner. As shown in
Advantageously, the proximal housing 304B can spin about the longitudinal axis independently of the distal housing 304A. As such, as the access assembly 309 advances into the patient, a distal face 306 of the distal housing 304A can contact a skin surface of the patient. The distal face 306 of the distal housing 304A can rest in a substantially stationary position against the skin surface, allowing the proximal housing 304B and/or needle 204 to rotate about the longitudinal axis until the medullary cavity is accessed. The distal housing 304A can mitigate friction between the access assembly 309 and the skin surface, preventing friction burns, or similar trauma.
In an embodiment, the distal housing 304A can slide independently of the proximal housing 304B and/or needle 204, along the longitudinal axis. In an embodiment, the needle hub 204 can further include a biasing member, e.g. compression spring, or the like, configured to bias the distal housing 304A towards a longitudinally distal position. In an embodiment, when a distal face 306 of the distal housing 304A contacts a skin surface of the patient, the proximal housing 304B and/or the needle 204 can continue to advance distally, along the longitudinal axis until the medullary cavity 90 is accessed. The distal housing 304A can rest on a skin surface and remain substantially stationary preventing compression or trauma of the surface tissues 70, 75 disposed between the distal face 306 and the bone cortex 80. This can be important where a thickness of the surface tissues 70, 75 can vary significantly between different patients.
Further, the distal face 306 can align with the skin surface 70 to stabilize the needle assembly 202 once the needle 204 has been placed correctly. In an embodiment, a stabilizing device can be attached to the needle hub 203 or distal housing 304A to further stabilize the needle assembly 202 relative to the skin surface 70. The biasing member disposed within the needle hub can be configured to apply sufficient pressure to the distal housing 304A to urge the distal face 306 against the skin surface 70 and stabilize the needle hub 204, without compressing the surface tissues 70, 75 between the distal face 306 and the bone cortex 80. In an embodiment, the distal face 306 can include an adhesive or the like to further stabilize the needle assembly 202 with the skin surface 70.
As shown in
In an embodiment, with the overtube 364 in the retracted position, a predetermined distance (x) between a distal tip of the overtube 364 that defines a stepped outer diameter 254 and a distal tip of the needle 205 can be sufficient to allow a bevel of the needle to access the medullary cavity 90. In the extended position, a distal tip of the overtube 364 can extend distally of the distal tip 205 of the needle 204. The needle hub 203 can include an overtube biasing member 366, e.g. a compression spring or the like, configured to bias the overtube 364 towards an extended position.
The needle hub 203 can further include a locking mechanism 340 configured to selectively retain the overtube 364 in a retracted position. As shown, the locking mechanism is disposed at a mid-section of the overtube 364, however, it will be appreciated that other configurations of locking mechanism 340 are also contemplated including disposing towards a proximal end. In the retracted position, the locking mechanism 340 can inhibit proximal movement of the overtube 364 relative to the needle 204 to maintain the predetermined distance (x) between the stepped portion 254 and the needle tip 205. Further, the locking mechanism in the locked configuration, can retain the overtube 364 to prevent distal advancement of the overtube 364 relative to the needle 204. In an embodiment, the locking mechanism 340 can be transitioned from the locked configuration to the unlocked configuration to allow the overtube biasing member 366 to urge the overtube 364 to the extended position. Advantageously, in the extended position, the overtube 364 can prevent accidental needle stick injuries when the needle 204 is withdrawn proximally from the patient.
In an embodiment, the locking mechanism 340 can be transitioned from the locked configuration to the unlocked configuration by rotating the proximal housing 304B relative to the distal housing 304A in one of a clockwise or anti-clockwise direction. Advantageously, the proximal housing 304B can include a gripping feature 308 configured to facilitate grasping the proximal housing 304B and rotating the proximal housing about the longitudinal axis. Exemplary gripping features 308 can include grooves, ridges, or similar structures, and/or can include different materials disposed on a surface of the proximal housing 304B that have an increased friction co-efficient, e.g. rubber, silicone, or the like, or combinations thereof. As shown, the gripping feature 308 is disposed on a flared portion 303B of the proximal housing 304B, however other configurations of gripping features are also contemplated. Often a user can be wearing gloves when manipulating the needle hub 203 and the increased diameter (d1) of the needle hub 203, the flared portion(s) 303, and/or gripping feature(s) 308 can facilitate manipulation of the needle hub 203 even with gloves on.
In an embodiment, the locking mechanism 340 can be transitioned from the locked configuration to the unlocked configuration by sliding the proximal housing 304B relative to the distal housing 304A, along a longitudinal axis. For example, a user can grasp the proximal housing 304B and slide proximally away from the distal housing along the longitudinal housing to activate one or more cantilever systems that can transition the locking mechanism from the locked configuration to the unlocked configuration. In the unlocked configuration the biasing member 366 can urge the overtube 364 distally to the extended position, as described herein. As will be appreciated, the distal flared portion 303A and the proximal flared portion 303B can facilitate grasping the respective distal housing 304A and proximal housing 304B and sliding longitudinally apart, as described herein.
As shown in
In an exemplary method of use, as shown in
As shown in
In an embodiment, prior to insertion of the needle 204, the overtube 364 can be biased towards the extended position. The needle 204 and overtube 364 can be advanced through the surface tissues 70, 75 until a distal tip of the overtube 364 contacts the bone cortex 80. The driver 101 can be activated to drill the needle 204 through the bone cortex 80. As the needle 204 advances, the overtube 364 can transition towards the retracted position.
In an embodiment, the distal surface 306 of the needle hub 203 can abut against the skin surface. As noted, the distal housing 304A can be configured to contact the skin surface and remain substantially stationary while allowing the needle 204 and/or proximal housing 304B to continue to rotate. Advantageously, then distal housing 308A can prevent friction burns, or similar trauma between the needle hub 203 and the skin surface 70.
In an embodiment, the distal surface 306 can contact the skin surface 70 prior to the stepped portion 254 contacting the bone cortex 80, or prior to the overtube 364 fully transitioning to the retracted position. As noted, the distal housing 304A can be slidably engaged with the needle hub 203 and configured to allow the needle 204 to continue to advance distally while the distal housing 304A rests on a skin surface 70. Advantageously, this can prevent the soft tissues 70, 75 from being compressed between the distal face 306 and the bone cortex 80 and stabilizes the needle hub 203 with the skin surface 70. In an embodiment, the distal housing 304A configured as such, can allow a stabilizing device to be attached to the needle hub 203 or the distal housing 304A to further stabilize the needle assembly 202 relative to the skin surface 70. Optionally, when the overtube 364 has fully transitioned to the retracted configuration, the locking mechanism can be configured to automatically retain the overtube 364 in the retracted position.
As shown in
With the locking mechanism 340 in the unlocked configuration, the overtube biasing member 366 can urge the overtube 364 distally and transition the overtube 364 from the retracted position to the extended position, either as the needle 204 is withdrawn from the insertion site, or optionally, after the needle is withdrawn from the insertion site. In an embodiment, the biasing member 366 can maintain the overtube 364 in the extended configuration to prevent accidental needle stick injuries. In an embodiment, the needle hub 203 can further include an abutment 368 configured to engage the overtube 364, or portion thereof, and maintain the overtube 364 in the extended configuration to prevent accidental needle stick injuries.
Advantageously, embodiments disclosed herein provide a change in needle outer diameter that is abrupt enough to substantial increase resistance to insertion. This change in insertion resistance indicates the needle tip is correctly placed. In an embodiment, the change in resistance prevents the needle from being inserted past the outer diameter step. This removes any subjective assessment as to when to stop advancing the needle. Accordingly, embodiments can be deployed by users who don't have specialized training or regular practice at placing intraosseous devices. This is especially important since placing intraosseous devices often occur in emergency situations where users may not have specialized training or regular practice, yet need to quickly access a medullary cavity for vascular access.
While some particular embodiments have been disclosed herein, and while the particular embodiments have been disclosed in some detail, it is not the intention for the particular embodiments to limit the scope of the concepts provided herein. Additional adaptations and/or modifications can appear to those of ordinary skill in the art, and, in broader aspects, these adaptations and/or modifications are encompassed as well. Accordingly, departures may be made from the particular embodiments disclosed herein without departing from the scope of the concepts provided herein.
This application claims the benefit of priority to U.S. Provisional Application No. 62/907,450, filed Sep. 27, 2019, which is incorporated by reference in its entirety into this application.
Number | Name | Date | Kind |
---|---|---|---|
2773501 | Young | Dec 1956 | A |
3071135 | Baldwin et al. | Jan 1963 | A |
3166189 | Disston | Jan 1965 | A |
3329261 | Serany, Jr. et al. | Jul 1967 | A |
D222312 | Kurtz et al. | Oct 1971 | S |
3802555 | Grasty et al. | Apr 1974 | A |
3815605 | Schmidt et al. | Jun 1974 | A |
3991765 | Cohen | Nov 1976 | A |
4010737 | Vilaghy et al. | Mar 1977 | A |
4153160 | Leigh | May 1979 | A |
4226328 | Beddow | Oct 1980 | A |
4266555 | Jamshidi | May 1981 | A |
4314565 | Lee | Feb 1982 | A |
4383530 | Bruno | May 1983 | A |
4501363 | Isbey, Jr. | Feb 1985 | A |
4595102 | Cianci et al. | Jun 1986 | A |
4838282 | Strasser et al. | Jun 1989 | A |
4889529 | Haindl | Dec 1989 | A |
4925448 | Bazaral | May 1990 | A |
4952207 | Lemieux | Aug 1990 | A |
4964854 | Luther | Oct 1990 | A |
4969870 | Kramer et al. | Nov 1990 | A |
5040542 | Gray | Aug 1991 | A |
5042558 | Hussey et al. | Aug 1991 | A |
5053017 | Chamuel | Oct 1991 | A |
5098391 | Pantages et al. | Mar 1992 | A |
5122114 | Miller et al. | Jun 1992 | A |
5207697 | Carusillo et al. | May 1993 | A |
5263939 | Wortrich | Nov 1993 | A |
5290267 | Zimmermann | Mar 1994 | A |
5312364 | Jacobs | May 1994 | A |
5322163 | Foos | Jun 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5364367 | Banks et al. | Nov 1994 | A |
5372583 | Roberts et al. | Dec 1994 | A |
5406940 | Melzer et al. | Apr 1995 | A |
5451210 | Kramer et al. | Sep 1995 | A |
5525314 | Hurson | Jun 1996 | A |
5554154 | Rosenberg | Sep 1996 | A |
5575780 | Saito | Nov 1996 | A |
5591188 | Waisman | Jan 1997 | A |
5601559 | Melker et al. | Feb 1997 | A |
5688249 | Chang et al. | Nov 1997 | A |
5746720 | Stouder, Jr. | May 1998 | A |
5772678 | Thomason et al. | Jun 1998 | A |
5779708 | Wu | Jul 1998 | A |
5807275 | Jamshidi | Sep 1998 | A |
5810738 | Thomas, II | Sep 1998 | A |
5810826 | Åkerfeldt et al. | Sep 1998 | A |
5817052 | Johnson et al. | Oct 1998 | A |
5853393 | Bogert | Dec 1998 | A |
5868684 | Åkerfeldt et al. | Feb 1999 | A |
5868711 | Kramer et al. | Feb 1999 | A |
5871470 | McWha | Feb 1999 | A |
5885293 | McDevitt | Mar 1999 | A |
5927976 | Wu | Jul 1999 | A |
5947890 | Spencer et al. | Sep 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5967143 | Klappenberger | Oct 1999 | A |
5990382 | Fox | Nov 1999 | A |
6012586 | Misra | Jan 2000 | A |
6068121 | McGlinch | May 2000 | A |
6117108 | Woehr et al. | Sep 2000 | A |
6135769 | Kwan | Oct 2000 | A |
6210373 | Allmon | Apr 2001 | B1 |
6210376 | Grayson | Apr 2001 | B1 |
6228088 | Miller et al. | May 2001 | B1 |
6247928 | Meller et al. | Jun 2001 | B1 |
6273715 | Meller et al. | Aug 2001 | B1 |
6419490 | Kitchings Weathers, Jr. | Jul 2002 | B1 |
6458117 | Pollins, Sr. | Oct 2002 | B1 |
6527778 | Athanasiou et al. | Mar 2003 | B2 |
6602214 | Heinz et al. | Aug 2003 | B2 |
6626887 | Wu | Sep 2003 | B1 |
6629959 | Kuracina et al. | Oct 2003 | B2 |
6641395 | Kumar et al. | Nov 2003 | B2 |
6652490 | Howell | Nov 2003 | B2 |
6692471 | Boudreaux | Feb 2004 | B2 |
6761726 | Findlay et al. | Jul 2004 | B1 |
6814734 | Chappuis et al. | Nov 2004 | B2 |
6830562 | Mogensen et al. | Dec 2004 | B2 |
6875219 | Arramon et al. | Apr 2005 | B2 |
6905486 | Gibbs | Jun 2005 | B2 |
6916292 | Morawski et al. | Jul 2005 | B2 |
6984213 | Horner et al. | Jan 2006 | B2 |
6991096 | Gottlieb et al. | Jan 2006 | B2 |
6997907 | Safabash et al. | Feb 2006 | B2 |
7112191 | Daga | Sep 2006 | B2 |
7135031 | Flint | Nov 2006 | B2 |
7179244 | Smith et al. | Feb 2007 | B2 |
7214208 | Vaillancourt et al. | May 2007 | B2 |
7278987 | Solazzo | Oct 2007 | B2 |
7347838 | Kulli | Mar 2008 | B2 |
7347840 | Findlay et al. | Mar 2008 | B2 |
7399306 | Reiley et al. | Jul 2008 | B2 |
7407493 | Cane' | Aug 2008 | B2 |
7410053 | Bowen et al. | Aug 2008 | B2 |
7434687 | Itou et al. | Oct 2008 | B2 |
7458954 | Ferguson et al. | Dec 2008 | B2 |
7513888 | Sircom et al. | Apr 2009 | B2 |
7530965 | Villa et al. | May 2009 | B2 |
7534227 | Kulli | May 2009 | B2 |
7569033 | Greene et al. | Aug 2009 | B2 |
7582102 | Heinz et al. | Sep 2009 | B2 |
7588559 | Aravena et al. | Sep 2009 | B2 |
7658725 | Bialecki et al. | Feb 2010 | B2 |
7670328 | Miller | Mar 2010 | B2 |
7699807 | Faust et al. | Apr 2010 | B2 |
7699850 | Miller | Apr 2010 | B2 |
7736332 | Carlyon et al. | Jun 2010 | B2 |
7743918 | Itou et al. | Jun 2010 | B2 |
7749225 | Chappuis et al. | Jul 2010 | B2 |
7798994 | Brimhall | Sep 2010 | B2 |
7811260 | Miller et al. | Oct 2010 | B2 |
7815642 | Miller | Oct 2010 | B2 |
7828773 | Swisher et al. | Nov 2010 | B2 |
7828774 | Harding et al. | Nov 2010 | B2 |
7833204 | Picha | Nov 2010 | B2 |
7842038 | Haddock et al. | Nov 2010 | B2 |
7850620 | Miller et al. | Dec 2010 | B2 |
7850650 | Breitweiser | Dec 2010 | B2 |
D633199 | MacKay et al. | Feb 2011 | S |
7899528 | Miller et al. | Mar 2011 | B2 |
7900549 | Kobayashi | Mar 2011 | B2 |
7905857 | Swisher | Mar 2011 | B2 |
7951089 | Miller | May 2011 | B2 |
7955297 | Radmer et al. | Jun 2011 | B2 |
7972339 | Nassiri et al. | Jul 2011 | B2 |
7976498 | Swisher et al. | Jul 2011 | B2 |
7976502 | Baid | Jul 2011 | B2 |
8038664 | Miller et al. | Oct 2011 | B2 |
8043253 | Kraft et al. | Oct 2011 | B2 |
8043265 | Abe et al. | Oct 2011 | B2 |
8096973 | Snow et al. | Jan 2012 | B2 |
8142365 | Miller | Mar 2012 | B2 |
8152771 | Mogensen et al. | Apr 2012 | B2 |
8162904 | Takano et al. | Apr 2012 | B2 |
8167899 | Justis et al. | May 2012 | B2 |
8231547 | Deck et al. | Jul 2012 | B2 |
8235945 | Baid | Aug 2012 | B2 |
8240468 | Wilkinson et al. | Aug 2012 | B2 |
8246584 | Aravena et al. | Aug 2012 | B2 |
8273053 | Saltzstein | Sep 2012 | B2 |
8292891 | Browne et al. | Oct 2012 | B2 |
8308693 | Miller et al. | Nov 2012 | B2 |
8333769 | Browne et al. | Dec 2012 | B2 |
8356598 | Rumsey | Jan 2013 | B2 |
8357163 | Sidebotham et al. | Jan 2013 | B2 |
8388623 | Browne et al. | Mar 2013 | B2 |
8414539 | Kuracina et al. | Apr 2013 | B1 |
8419683 | Miller et al. | Apr 2013 | B2 |
8480632 | Miller et al. | Jul 2013 | B2 |
8480672 | Browne et al. | Jul 2013 | B2 |
8486027 | Findlay et al. | Jul 2013 | B2 |
8506568 | Miller | Aug 2013 | B2 |
8529576 | Krueger et al. | Sep 2013 | B2 |
8535271 | Fuchs et al. | Sep 2013 | B2 |
8562615 | Browne et al. | Oct 2013 | B2 |
8584849 | McCaffrey | Nov 2013 | B2 |
8641715 | Miller | Feb 2014 | B2 |
8647257 | Jansen et al. | Feb 2014 | B2 |
8656929 | Miller et al. | Feb 2014 | B2 |
8657790 | Tal et al. | Feb 2014 | B2 |
8662306 | Agrawal | Mar 2014 | B2 |
8663231 | Browne et al. | Mar 2014 | B2 |
8668698 | Miller et al. | Mar 2014 | B2 |
8684978 | Miller et al. | Apr 2014 | B2 |
8690791 | Miller | Apr 2014 | B2 |
8715287 | Miller | May 2014 | B2 |
8758383 | Geist | Jun 2014 | B2 |
8771230 | White et al. | Jul 2014 | B2 |
8801663 | Woehr | Aug 2014 | B2 |
8812101 | Miller et al. | Aug 2014 | B2 |
8814835 | Baid | Aug 2014 | B2 |
8828001 | Stearns et al. | Sep 2014 | B2 |
8870872 | Miller | Oct 2014 | B2 |
8893883 | Valaie et al. | Nov 2014 | B2 |
D720471 | Angel et al. | Dec 2014 | S |
8936575 | Moulton | Jan 2015 | B2 |
8944069 | Miller et al. | Feb 2015 | B2 |
8974410 | Miller et al. | Mar 2015 | B2 |
8998848 | Miller et al. | Apr 2015 | B2 |
9072543 | Miller et al. | Jul 2015 | B2 |
9078637 | Miller | Jul 2015 | B2 |
9131925 | Kraft et al. | Sep 2015 | B2 |
9149625 | Woehr et al. | Oct 2015 | B2 |
9173679 | Tzachar et al. | Nov 2015 | B2 |
9186217 | Goyal | Nov 2015 | B2 |
9226756 | Teisen et al. | Jan 2016 | B2 |
9278195 | Erskine | Mar 2016 | B2 |
9295487 | Miller et al. | Mar 2016 | B2 |
9302077 | Domonkos et al. | Apr 2016 | B2 |
9314232 | Stark | Apr 2016 | B2 |
9314270 | Miller | Apr 2016 | B2 |
9358348 | Weilbacher et al. | Jun 2016 | B2 |
9393031 | Miller | Jul 2016 | B2 |
9414815 | Miller et al. | Aug 2016 | B2 |
9415192 | Kuracina et al. | Aug 2016 | B2 |
9421345 | Woehr et al. | Aug 2016 | B2 |
9427555 | Baid | Aug 2016 | B2 |
9433400 | Miller | Sep 2016 | B2 |
9439667 | Miller | Sep 2016 | B2 |
9439702 | Arthur et al. | Sep 2016 | B2 |
9451968 | Miller et al. | Sep 2016 | B2 |
9451983 | Windolf | Sep 2016 | B2 |
9480483 | Browne et al. | Nov 2016 | B2 |
9486604 | Murray et al. | Nov 2016 | B2 |
9504477 | Miller et al. | Nov 2016 | B2 |
9545243 | Miller et al. | Jan 2017 | B2 |
9615816 | Woodard | Apr 2017 | B2 |
9615838 | Nino et al. | Apr 2017 | B2 |
9623210 | Woehr | Apr 2017 | B2 |
9636484 | Baid | May 2017 | B2 |
9681889 | Greenhalgh et al. | Jun 2017 | B1 |
9687633 | Teoh | Jun 2017 | B2 |
9717564 | Miller et al. | Aug 2017 | B2 |
9730729 | Kilcoin et al. | Aug 2017 | B2 |
9744333 | Terzibashian | Aug 2017 | B2 |
9782546 | Woehr | Oct 2017 | B2 |
9788843 | Teisen | Oct 2017 | B2 |
9839740 | Beamer et al. | Dec 2017 | B2 |
9844646 | Knutsson | Dec 2017 | B2 |
9844647 | Knutsson | Dec 2017 | B2 |
9872703 | Miller et al. | Jan 2018 | B2 |
9883853 | Woodard et al. | Feb 2018 | B2 |
9895512 | Kraft et al. | Feb 2018 | B2 |
9962211 | Csernatoni | May 2018 | B2 |
9999444 | Geist et al. | Jun 2018 | B2 |
10022464 | Sarphati et al. | Jul 2018 | B2 |
10039897 | Norris et al. | Aug 2018 | B2 |
10052111 | Miller et al. | Aug 2018 | B2 |
10064694 | Connolly | Sep 2018 | B2 |
10070933 | Adler et al. | Sep 2018 | B2 |
10070934 | Kerns et al. | Sep 2018 | B2 |
10080864 | Terzibashian | Sep 2018 | B2 |
10092320 | Morgan et al. | Oct 2018 | B2 |
10106295 | Lockwood | Oct 2018 | B2 |
10130343 | Miller et al. | Nov 2018 | B2 |
10136878 | Tzachar et al. | Nov 2018 | B2 |
10182878 | Goyal | Jan 2019 | B2 |
10238420 | Karve et al. | Mar 2019 | B2 |
10245010 | Miller et al. | Apr 2019 | B2 |
10251812 | Tomes et al. | Apr 2019 | B2 |
10258783 | Miller et al. | Apr 2019 | B2 |
10314629 | Park | Jun 2019 | B2 |
10405938 | Ramsey | Sep 2019 | B2 |
10441454 | Tanghoej et al. | Oct 2019 | B2 |
10456149 | Miller | Oct 2019 | B2 |
10456497 | Howell et al. | Oct 2019 | B2 |
10595896 | Miller | Mar 2020 | B2 |
10722247 | Browne et al. | Jul 2020 | B2 |
10893887 | Blanchard | Jan 2021 | B2 |
20030060781 | Mogensen et al. | Mar 2003 | A1 |
20030225344 | Miller | Dec 2003 | A1 |
20030225411 | Miller | Dec 2003 | A1 |
20030229308 | Tsals et al. | Dec 2003 | A1 |
20040162559 | Arramon et al. | Aug 2004 | A1 |
20040220497 | Findlay et al. | Nov 2004 | A1 |
20040243135 | Koseki | Dec 2004 | A1 |
20050033235 | Flint | Feb 2005 | A1 |
20050035014 | Cane | Feb 2005 | A1 |
20050101912 | Faust et al. | May 2005 | A1 |
20050113866 | Heinz et al. | May 2005 | A1 |
20050148940 | Miller | Jul 2005 | A1 |
20050165403 | Miller | Jul 2005 | A1 |
20050261693 | Miller et al. | Nov 2005 | A1 |
20060015066 | Turieo et al. | Jan 2006 | A1 |
20060025723 | Ballarini | Feb 2006 | A1 |
20070016138 | Swisher et al. | Jan 2007 | A1 |
20070049945 | Miller | Mar 2007 | A1 |
20070191772 | Wojcik | Aug 2007 | A1 |
20070270775 | Miller et al. | Nov 2007 | A1 |
20080086142 | Kohm et al. | Apr 2008 | A1 |
20080119759 | McLain | May 2008 | A1 |
20080119821 | Agnihotri et al. | May 2008 | A1 |
20080140014 | Miller et al. | Jun 2008 | A1 |
20080154304 | Crawford et al. | Jun 2008 | A1 |
20080208136 | Findlay et al. | Aug 2008 | A1 |
20080215056 | Miller et al. | Sep 2008 | A1 |
20080221580 | Miller et al. | Sep 2008 | A1 |
20080257359 | Rumsey | Oct 2008 | A1 |
20090048575 | Waters | Feb 2009 | A1 |
20090054808 | Miller | Feb 2009 | A1 |
20090093830 | Miller | Apr 2009 | A1 |
20090105775 | Mitchell et al. | Apr 2009 | A1 |
20090118639 | Moos et al. | May 2009 | A1 |
20090204024 | Miller | Aug 2009 | A1 |
20090228014 | Stearns | Sep 2009 | A1 |
20090306697 | Fischvogt | Dec 2009 | A1 |
20100030105 | Noishiki et al. | Feb 2010 | A1 |
20100082033 | Germain | Apr 2010 | A1 |
20100152616 | Beyhan et al. | Jun 2010 | A1 |
20100204649 | Miller et al. | Aug 2010 | A1 |
20100280410 | Moos et al. | Nov 2010 | A1 |
20100286607 | Saltzstein | Nov 2010 | A1 |
20100298830 | Browne et al. | Nov 2010 | A1 |
20100298831 | Browne et al. | Nov 2010 | A1 |
20100312246 | Browne et al. | Dec 2010 | A1 |
20110004163 | Vaidya | Jan 2011 | A1 |
20110028976 | Miller | Feb 2011 | A1 |
20110137253 | Simonton et al. | Jun 2011 | A1 |
20120041454 | Johnstone | Feb 2012 | A1 |
20120202180 | Stock et al. | Aug 2012 | A1 |
20120203154 | Tzachar | Aug 2012 | A1 |
20130030439 | Browne et al. | Jan 2013 | A1 |
20130041345 | Kilcoin et al. | Feb 2013 | A1 |
20130072938 | Browne et al. | Mar 2013 | A1 |
20130079720 | Finnestad et al. | Mar 2013 | A1 |
20130102924 | Findlay et al. | Apr 2013 | A1 |
20130158484 | Browne et al. | Jun 2013 | A1 |
20130178807 | Baid | Jul 2013 | A1 |
20130331840 | Teisen | Dec 2013 | A1 |
20140039400 | Browne et al. | Feb 2014 | A1 |
20140046327 | Tzachar et al. | Feb 2014 | A1 |
20140074102 | Mandeen et al. | Mar 2014 | A1 |
20140081281 | Felder | Mar 2014 | A1 |
20140142577 | Miller | May 2014 | A1 |
20140262408 | Woodard | Sep 2014 | A1 |
20140262880 | Yoon | Sep 2014 | A1 |
20140276205 | Miller et al. | Sep 2014 | A1 |
20140276206 | Woodward et al. | Sep 2014 | A1 |
20140276366 | Bourne et al. | Sep 2014 | A1 |
20140276471 | Emery et al. | Sep 2014 | A1 |
20140276833 | Larsen et al. | Sep 2014 | A1 |
20140276839 | Forman et al. | Sep 2014 | A1 |
20140343454 | Miller et al. | Nov 2014 | A1 |
20140343497 | Baid | Nov 2014 | A1 |
20150011941 | Saeki | Jan 2015 | A1 |
20150126931 | Holm et al. | May 2015 | A1 |
20150127006 | Miller | May 2015 | A1 |
20150196737 | Baid | Jul 2015 | A1 |
20150223786 | Morgan et al. | Aug 2015 | A1 |
20150230823 | Morgan et al. | Aug 2015 | A1 |
20150238733 | bin Abdulla | Aug 2015 | A1 |
20150342615 | Keinan et al. | Dec 2015 | A1 |
20150342756 | Bays et al. | Dec 2015 | A1 |
20150351797 | Miller et al. | Dec 2015 | A1 |
20150366569 | Miller | Dec 2015 | A1 |
20160022282 | Miller et al. | Jan 2016 | A1 |
20160058432 | Miller | Mar 2016 | A1 |
20160066954 | Miller et al. | Mar 2016 | A1 |
20160106441 | Teisen | Apr 2016 | A1 |
20160136410 | Aklog et al. | May 2016 | A1 |
20160183974 | Miller | Jun 2016 | A1 |
20160228676 | Glithero et al. | Aug 2016 | A1 |
20160235949 | Baid | Aug 2016 | A1 |
20160354539 | Tan et al. | Dec 2016 | A1 |
20160361519 | Teoh et al. | Dec 2016 | A1 |
20170021138 | Sokolski | Jan 2017 | A1 |
20170043135 | Knutsson | Feb 2017 | A1 |
20170056122 | Ramsey | Mar 2017 | A1 |
20170105763 | Karve et al. | Apr 2017 | A1 |
20170136217 | Riesenberger et al. | May 2017 | A1 |
20170143395 | Park | May 2017 | A1 |
20170151419 | Sonksen | Jun 2017 | A1 |
20170156740 | Stark | Jun 2017 | A9 |
20170156751 | Csernatoni | Jun 2017 | A1 |
20170209129 | Fagundes et al. | Jul 2017 | A1 |
20170303962 | Browne et al. | Oct 2017 | A1 |
20170303963 | Kilcoin et al. | Oct 2017 | A1 |
20180092662 | Rioux et al. | Apr 2018 | A1 |
20180116642 | Woodard et al. | May 2018 | A1 |
20180116693 | Blanchard et al. | May 2018 | A1 |
20180117262 | Islam | May 2018 | A1 |
20180125465 | Muse et al. | May 2018 | A1 |
20180154112 | Chan et al. | Jun 2018 | A1 |
20180206933 | Healey et al. | Jul 2018 | A1 |
20180221564 | Patel et al. | Aug 2018 | A1 |
20180236182 | Charlebois et al. | Aug 2018 | A1 |
20180256209 | Muse et al. | Sep 2018 | A1 |
20190021807 | Barnell et al. | Jan 2019 | A1 |
20190060607 | Yabu et al. | Feb 2019 | A1 |
20190076132 | Tzachar et al. | Mar 2019 | A1 |
20190125404 | Shippert | May 2019 | A1 |
20190150953 | Budyansky | May 2019 | A1 |
20190151606 | Mottola et al. | May 2019 | A1 |
20190201053 | Ben Mocha et al. | Jul 2019 | A1 |
20190282244 | Muse | Sep 2019 | A1 |
20190328370 | Muse | Oct 2019 | A1 |
20190343556 | Coppedge et al. | Nov 2019 | A1 |
20210093358 | Lindekugel | Apr 2021 | A1 |
20210137558 | Lindekugel | May 2021 | A1 |
20240050126 | Blanchard | Feb 2024 | A1 |
Number | Date | Country |
---|---|---|
0232600 | Aug 1987 | EP |
0548612 | Jun 1993 | EP |
1997024151 | Jul 1997 | WO |
1998052638 | Feb 1999 | WO |
2004000408 | Dec 2003 | WO |
2004073500 | Sep 2004 | WO |
2005046769 | May 2005 | WO |
05041790 | May 2005 | WO |
2005053506 | Jun 2005 | WO |
2005072625 | Aug 2005 | WO |
2006047737 | May 2006 | WO |
2007018809 | Feb 2007 | WO |
2008002961 | Jan 2008 | WO |
2008016757 | Feb 2008 | WO |
2008033871 | Mar 2008 | WO |
2008033872 | Mar 2008 | WO |
2008033873 | Mar 2008 | WO |
2008033874 | Mar 2008 | WO |
2008054894 | May 2008 | WO |
2008086258 | Jul 2008 | WO |
2008124206 | Oct 2008 | WO |
2008124463 | Oct 2008 | WO |
2008130893 | Oct 2008 | WO |
2008134355 | Nov 2008 | WO |
2008144379 | Nov 2008 | WO |
2009070896 | Jun 2009 | WO |
2010043043 | Apr 2010 | WO |
2011097311 | Aug 2011 | WO |
2011139294 | Nov 2011 | WO |
2013009901 | Jan 2013 | WO |
2013173360 | Nov 2013 | WO |
2014142948 | Sep 2014 | WO |
2014144239 | Sep 2014 | WO |
2014144262 | Sep 2014 | WO |
2014144489 | Sep 2014 | WO |
2014144757 | Sep 2014 | WO |
2014144797 | Sep 2014 | WO |
2015177612 | Nov 2015 | WO |
2016033016 | Mar 2016 | WO |
16053834 | Apr 2016 | WO |
2016163939 | Oct 2016 | WO |
18006045 | Jan 2018 | WO |
2018025094 | Feb 2018 | WO |
2018058036 | Mar 2018 | WO |
2018075694 | Apr 2018 | WO |
18098086 | May 2018 | WO |
2018165334 | Sep 2018 | WO |
2018165339 | Sep 2018 | WO |
2019051343 | Mar 2019 | WO |
2019051412 | Mar 2019 | WO |
2019164990 | Aug 2019 | WO |
2019215705 | Nov 2019 | WO |
2020012051 | Jan 2020 | WO |
2021062215 | Apr 2021 | WO |
2021173649 | Sep 2021 | WO |
Entry |
---|
PCT/US2021/042040 filed Jul. 16, 2021 International Search Report and Written Opinion dated Oct. 4, 2021. |
PCT/US2020/052809 filed Sep. 25, 2020 International Search Report and Written Opinion dated Jan. 5, 2021. |
EP 17861304.8 filed Apr. 16, 2019 Extended European Search Report filed Jul. 28, 2020. |
EP 17864208.8 filed May 24, 2019 Extended European Search Report filed May 19, 2020. |
PCT/US 17/57270 filed Oct. 18, 2017 International Search Report and Written Opinion dated Jan. 12, 2018. |
PCT/US2017/058863 filed Oct. 27, 2017 International Search Report and Written Opinion dated Jan. 29, 2018. |
PCT/US2018/021398 filed Mar. 7, 2018 International search report and written opinion dated May 21, 2018. |
U.S. Appl. No. 15/796,471, filed Oct. 27, 2017 Advisory Action dated Jun. 15, 2020. |
U.S. Appl. No. 15/796,471, filed Oct. 27, 2017 Final Office Action dated Apr. 23, 2020. |
U.S. Appl. No. 15/796,471, filed Oct. 27, 2017 Non-Final Office Action dated Oct. 30, 2019. |
U.S. Appl. No. 15/796,471, filed Oct. 27, 2017 Notice of Allowance dated Jun. 15, 2020. |
U.S. Appl. No. 15/796,471, filed Oct. 27, 2017 Restriction Requirement dated Jul. 8, 2019. |
U.S. Appl. No. 17/152,509, filed Jan. 19, 2021 Non-Final Office Action dated May 4, 2023. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Non Final Office Action dated May 30, 2023. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Restriction Requirement dated Feb. 13, 2023. |
EP 20868558.6 filed Apr. 21, 2022 Extended European Search Report dated Aug. 11, 2023. |
U.S. Appl. No. 17/152,509, filed Jan. 19, 2021 Notice of Allowance dated Sep. 7, 2023. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Final Office Action dated Sep. 28, 2023. |
PCT/US2021/019388 filed Feb. 24, 2021 International Search Report and Written Opinion dated May 17, 2021. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Advisory Action dated Nov. 2, 2023. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Non-Final Office Action dated Dec. 27, 2023. |
U.S. Appl. No. 17/183,820, filed Feb. 24, 2021 Final Office Action dated May 29, 2024. |
U.S. Appl. No. 17/378,304, filed Jul. 16, 2021 Non-Final Office Action dated Jun. 5, 2024. |
Number | Date | Country | |
---|---|---|---|
20210093358 A1 | Apr 2021 | US |
Number | Date | Country | |
---|---|---|---|
62907450 | Sep 2019 | US |